Skip to main content
. 2017 Dec 14;17:852. doi: 10.1186/s12885-017-3803-6

Fig. 2.

Fig. 2

Overall survival among patients with AML-MRC. a Overall survival for all patients with AML-MRC treated with azacitidine or CCR. b Sensitivity analysis, in which patients who switched to alternate therapy were censored at the time they did so. c Overall survival by NCCN cytogenetic risk. d Overall survival by age group